Recent introduction of monoclonal antibodies targeting immune checkpoints to harness
antitumor immunity has revolutionized the cancer treatment landscape. The therapeutic …

Advances in understanding the physiologic functions of the tumor necrosis factor
superfamily (TNFSF) of ligands, receptors, and signaling networks are providing deeper …

Glioblastomas are aggressive brain tumors that are largely immunotherapy resistant. This is
associated with immunosuppression and a dysfunctional tumor vasculature, which hinder T …

The engagement of the herpesvirus entry mediator (HVEM, TNFRSF14) by the B and T
lymphocyte attenuator (BTLA) represents a unique interaction between an activating …

Background The clinical predictors and biological mechanisms for localized prostate cancer
(PCa) outcomes remain mostly unknown. We aim to evaluate the role of serum immune …

Pediatric nodal marginal zone lymphoma (PNMZL) is an uncommon B-cell neoplasm
affecting mainly male children and young adults. This indolent lymphoma has distinct …

Simple Summary Chronic lymphocytic leukemia (CLL) represents the most frequent B cell
malignancy in Western countries and still remains as an incurable disease. Despite recent …

Patients with chronic lymphocytic leukemia (CLL) progressively develop marked
immunosuppression, dampening innate and adaptive-driven antitumor responses. However …

Current molecular classification approaches for endometrial cancer (EC) often employ
multiple testing platforms. Some subtypes still lack univocal prognostic significance …

HVEM is a TNF (tumor necrosis factor) receptor contributing to a broad range of immune
functions involving diverse cell types. It interacts with a TNF ligand, LIGHT, and …